18 ± 0.28 18.34 ± 0.36* 20.03 ± 0.32 19.17 ± 0.44 Distance in last 15 mins(km) 6.65 ± 0.11 5.84 ± 0.16* 6.67 ± 0.12 6.32 ± 0.18 selleck kinase inhibitor Average Speed (km.hr-1) 26.89 ± 0.39 24.67 ± 0.46* 26.54 ± 0.36 25.70 ± 0.56 Average Speed – last 15 mins (km.hr-1) 27.05 ± 0.39 24.75 ± 0.49* 26.72 ± 0.43 25.64 ± 0.58 Values are presented as mean ± SE; n = 16; PL, Placebo; CPE, carbohydrate-protein-electrolyte; ST1, submaximal exercise trial 1, ST2, submaximal exercise trial 2. * denotes significant difference (P = 0.0001) between trials within condition only. Data for average power output are shown in Figures 1 and 2. During submaximal exercise, Rigosertib supplier there was a significant
interaction effect for average power this website output (F = 7.637; P = 0.015). Over the full 45 minute trial, power output significantly decreased by 10.9% from 128.89 ± 3.61 W in ST1 to 114.82 ± 4.04 W in ST2 (P = 0.002) for PL only. A similar pattern was observed for the last 15 minutes of the exercise trial, with average power output being significantly lower in ST2 (112.38 ± 4.22 W) compared to ST1 (128.38 ± 3.85 W) for
PL only (P = 0.0001). No significant differences were found for the CPE beverage between trials. Figure 1 Assessment of test beverages on average power output watts) during submaximal exercise trials. Data is presented as mean ± SE; n = 16. PL, Placebo; CPE, carbohydrate-protein-electrolyte; ST1, submaximal exercise trial 1, ST2, submaximal exercise trial 2. * denotes significant difference P = 0.002) between trials within condition only. Figure 2 Assessment of test beverages on average power output watts) during final 15 minutes of submaximal exercise trials. Data is presented as mean
± SE; n = 16. PL, Placebo; CPE, carbohydrate-protein-electrolyte; ST1, submaximal exercise trial 1, ST2, submaximal exercise trial 2. * denotes significant difference P = 0.0001) between trials within condition only. Cardio-respiratory and subjective exertion data Data for submaximal cardiorespiratory variables, total oxidation rates and RPE data are represented in Table 3. No significant differences were found within condition or between trials for oxygen Histone demethylase consumption (VO2) (P > 0.05), demonstrating adherence to the exercise intensity. There was, however, a significant difference between trials for carbon dioxide (VCO2) production (F = 18.814; P = 0.001). VCO2 was significantly lower in ST2 compared to ST1 for PL (1.816 ± 0.076 L.min-1 v 2.031 ± 0.100 L.min-1, P = 0.0001). There was also a significant difference in mean VCO2 in ST2 between PL and CPE (1.816 ± 0.076 L.min-1 v 1.914 ± 0.066 L.min-1 respectively, P = 0.029). Table 3 Comparison between test beverages on cardiorespiratory variables, total oxidation rates and subjective exertion data during submaximal exercise trials PL CPE ST 1 ST 2 ST 1 ST 2 VO2 (L.min-1) 2.040 ± 0.058 1.995 ± 0.071 2.062 ± 0.058 2.052 ± 0.071 VCO2 (L.min-1) 2.031 ± 0.100 1.816 ± 0.